Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study - Archive ouverte HAL Access content directly
Journal Articles Annals of Oncology Year : 2016

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

, (1) , , , , (1) , (2) , , (3) , , , , (4) , (5) , , , (6) , (7) , , , (8) , (9) , , , ,
1
2
3
4
5
6
7
8
9
S. Delaloge
  • Function : Author
C. Courtinard
  • Function : Author
E. Brain
  • Function : Author
B. Asselain
  • Function : Author
Thomas Bachelot
V. Dieras
  • Function : Author
C. Levy
  • Function : Author
W. Jacot
  • Function : Author
V. Lorgis
  • Function : Author
C. Veyret
  • Function : Author
M. Ferrero
  • Function : Author
L. Uwer
  • Function : Author
M. Mouret-Reynier
  • Function : Author
T. Petit
G. Chenuc
  • Function : Author
T. Guesmia
  • Function : Author
M. Robain
  • Function : Author
C. Cailliot
  • Function : Author

Dates and versions

hal-02262350 , version 1 (02-08-2019)

Identifiers

Cite

S. Delaloge, David Perol, C. Courtinard, E. Brain, B. Asselain, et al.. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study. Annals of Oncology, 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩. ⟨hal-02262350⟩
30 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More